Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population
JOURNAL OF HEPATOLOGY, cilt.68, sa.6, ss.1129-1136, 2018 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 68 Sayı: 6
- Basım Tarihi: 2018
- Doi Numarası: 10.1016/j.jhep.2018.01.031
- Dergi Adı: JOURNAL OF HEPATOLOGY
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.1129-1136
- Anahtar Kelimeler: Hepatitis B, Hepatocellular carcinoma, Cirrhosis, Antiviral therapy, Liver transplantation, HEPATOCELLULAR-CARCINOMA, VIRUS INFECTION, RECEIVING ENTECAVIR, ANTIVIRAL THERAPY, NATURAL-HISTORY, RISK, LAMIVUDINE, MORTALITY, MANAGEMENT, CIRRHOSIS
- Ankara Üniversitesi Adresli: Evet
Özet
Background & Aims: The effects of long-term antiviral therapy on survival have not been adequately assessed in chronic hepatitis B (CHB). In this 10-centre, ongoing cohort study, we evaluated the probability of survival and factors affecting survival in Caucasian CHB patients who received long-term entecavir/tenofovir therapy.